High Potent Manufacturing

Our specialized high potent manufacturing expertise is built on 35 years of experience in potent processing and offers a purpose-built facility utilizing the very latest in containment technology.

This enables the safe development and clinical and commercial supply of products with an occupational exposure limit (OEL) as low as 0.01µg/m3.

The facility itself has multiple levels of containment built into the design. Dispensing of API is undertaken within isolators and subsequent processes within appropriately contained equipment, ensuring operator safety and preventing cross-contamination. Our fully integrated facility utilizes common equipment trains from development to commercial scale, utilizing geometric scale-up to deliver reproducibility and ultimately speed-to-market.

  • Multiple compound processing
  • Development to commercial scale manufacturing and packaging
  • Segregated people and material flow
  • Secure access with client viewing gallery
  • Automated cleaning procedures
  • Contained engineering eliminating the need for personal protective equipment (PPE)
  • HVAC system with single pass air
  • Purpose-built, high performance, bespoke effluent treatment facility
  • Design-for-manufacture delivering true speed-to-market
  • Meeting regulatory standard for major markets including Japan, TMoH, the MHRA, FDA and ANVISA


We have produced an insightful whitepaper which examines the process of successfull high potency drug manufacturing and delivery to market.

We have produced an insightful whitepaper that examines the process of successful high potency drug manufacturing and delivery to market. Find out more about it and download it here

    Our dedicated team of specialists will be happy to discuss Specialized Manufacturing of Highly Potent Products with you. Contact us on +1 779-208-1819 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pciservices.com

    When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

    Your bridge between life-changing therapies and patients